Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-09-14
Recursion Pharmaceuticals, Inc.
Clinical-stage biotech using an AI-native discovery stack, automated labs, and pharma collaborations to find and develop small-molecule medicines.
ai automation biotech healthcare software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Platform Proof Before Platform Premium
The upside depends less on AI branding and more on turning discovery speed into owned drug economics. A credible REC-4881 path and one more internal human proof point could support a durable multi-asset rerating by 2031.

Analysis

Thesis
Recursion wins if its proprietary data, automated labs, and AI loop stop looking like an expensive discovery tool and start producing owned medicines plus repeatable partner milestones. Over five years, a credible REC-4881 registration path, one more internal human proof point, and better downstream economics can support a multi-asset biotech rerating.
Last Economy Alignment
Cheaper cognition should make Recursion’s data-lab-model loop more productive, and its value capture sits in proprietary data rights, workflow integration, and downstream drug economics rather than seat software. The gating risk is proof: if clinical translation stalls, the platform can be treated as a costly toolset instead of a compounding engine.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
4.0x (from 5 most recent analyses)
Reasoning
The upside is a mix-shift story: less dependence on fee-like collaboration revenue and more value from owned assets, milestones, royalties, and standardized verified workflows. If the lead rare-disease program earns an approval-oriented path and one more internal asset reaches meaningful human proof, investors can value the business more like a multi-asset biotech engine than a speculative AI tool vendor.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The main risk is proof conversion, not AI output volume. Recursion must show that its proprietary data and AI workflow create approval-oriented assets often enough to justify better pricing power, stronger partner economics, and future financing. If REC-4881 disappoints or the next internal proof point slips, the business can remain stuck in low-visibility collaboration revenue while dilution absorbs much of the operating progress.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.48
They control a data-and-lab loop that should get better as AI gets cheaper, so each improvement in models can create better drug shots on goal. The risk is simple: if that loop does not produce convincing human outcomes, customers and investors can treat it as an expensive tool rather than a must-have engine.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.22
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case